

Bruce A Perkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5212505/publications.pdf>

Version: 2024-02-01

195
papers

13,199
citations

30070

54
h-index

24258

110
g-index

196
all docs

196
docs citations

196
times ranked

11582
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus. <i>Circulation</i> , 2014, 129, 587-597.	1.6	1,045
2	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus. <i>Circulation</i> , 2016, 134, 752-772.	1.6	932
3	Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 311-320.	27.0	792
4	Regression of Microalbuminuria in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2003, 348, 2285-2293.	27.0	719
5	The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2014, 13, 28.	6.8	381
6	Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 501-512.	11.4	348
7	Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2002, 25, 2048-2052.	8.6	341
8	Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1353-1361.	6.1	325
9	Detection of Renal Function Decline in Patients with Diabetes and Normal or Elevated GFR by Serial Measurements of Serum Cystatin C Concentration. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1404-1412.	6.1	307
10	Association of Vitamin D With Insulin Resistance and β -Cell Dysfunction in Subjects at Risk for Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1379-1381.	8.6	287
11	Carpal Tunnel Syndrome in Patients With Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2002, 25, 565-569.	8.6	241
12	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , 2018, 41, 2560-2569.	8.6	239
13	In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. <i>Kidney International</i> , 2010, 77, 57-64.	5.2	231
14	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020, 382, 2493-2503.	27.0	228
15	Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. <i>Diabetes Care</i> , 2014, 37, 1480-1483.	8.6	211
16	Resistance Versus Aerobic Exercise. <i>Diabetes Care</i> , 2013, 36, 537-542.	8.6	184
17	Detection of Diabetic Sensorimotor Polyneuropathy by Corneal Confocal Microscopy in Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 821-828.	8.6	177
18	Effects of Performing Resistance Exercise Before Versus After Aerobic Exercise on Glycemia in Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 669-675.	8.6	154

#	ARTICLE	IF	CITATIONS
19	Normative Values for Corneal Nerve Morphology Assessed Using Corneal Confocal Microscopy: A Multinational Normative Data Set. <i>Diabetes Care</i> , 2015, 38, 838-843.	8.6	150
20	The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 1860-1870.	6.3	148
21	Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, F77-F83.	2.7	143
22	Diabetic neuropathy: a review emphasizing diagnostic methods. <i>Clinical Neurophysiology</i> , 2003, 114, 1167-1175.	1.5	139
23	Urinary Peptidome May Predict Renal Function Decline in Type 1 Diabetes and Microalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2065-2074.	6.1	136
24	Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. <i>Diabetologia</i> , 2014, 57, 2599-2602.	6.3	136
25	Corneal Confocal Microscopy Predicts 4-Year Incident Peripheral Neuropathy in Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 671-675.	8.6	129
26	Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. <i>Diabetes Care</i> , 2013, 36, 3208-3215.	8.6	128
27	Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study. <i>Current Diabetes Reports</i> , 2013, 13, 550-559.	4.2	127
28	Prospective Associations of Vitamin D With β -Cell Function and Glycemia. <i>Diabetes</i> , 2011, 60, 2947-2953.	0.6	124
29	Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. <i>Diabetes Research and Clinical Practice</i> , 2001, 54, 115-128.	2.8	123
30	Type 1 Diabetes and Vigorous Exercise: Applications of Exercise Physiology to Patient Management. <i>Canadian Journal of Diabetes</i> , 2006, 30, 63-71.	0.8	110
31	Association of 25(OH)D and PTH with Metabolic Syndrome and Its Traditional and Nontraditional Components. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 168-175.	3.6	107
32	Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients?. <i>Diabetes Care</i> , 2014, 37, 1418-1424.	8.6	105
33	Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. <i>Diabetes Care</i> , 2015, 38, 793-800.	8.6	104
34	Uric Acid as a Biomarker and a Therapeutic Target in Diabetes. <i>Canadian Journal of Diabetes</i> , 2015, 39, 239-246.	0.8	103
35	Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. <i>Diabetologia</i> , 2018, 61, 1856-1861.	6.3	103
36	Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study. <i>Diabetes Care</i> , 2011, 34, 2403-2405.	8.6	102

#	ARTICLE	IF	CITATIONS
37	Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 914-923.	2.2	99
38	Effect of omega-3 supplementation on neuropathy in type 1 diabetes. <i>Neurology</i> , 2017, 88, 2294-2301.	1.1	95
39	Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. <i>Kidney International</i> , 2014, 86, 1057-1058.	5.2	93
40	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1969-1977.	4.5	93
41	Can Ultrasound of the Tibial Nerve Detect Diabetic Peripheral Neuropathy?. <i>Diabetes Care</i> , 2012, 35, 2575-2579.	8.6	92
42	Efficacy of Continuous Real-Time Blood Glucose Monitoring During and After Prolonged High-Intensity Cycling Exercise: Spinning with a Continuous Glucose Monitoring System. <i>Diabetes Technology and Therapeutics</i> , 2006, 8, 627-635.	4.4	89
43	Structure-Function Relationship Between Corneal Nerves and Conventional Small-Fiber Tests in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2748-2755.	8.6	83
44	Prediction of Incident Diabetic Neuropathy Using the Monofilament Examination. <i>Diabetes Care</i> , 2010, 33, 1549-1554.	8.6	80
45	Renal Hyperfiltration and the Development of Microalbuminuria in Type 1 Diabetes. <i>Diabetes Care</i> , 2009, 32, 889-893.	8.6	76
46	Risk Factors for Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 883-890.	8.6	76
47	Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy. <i>PLoS ONE</i> , 2014, 9, e86515.	2.5	72
48	Insulin Pump Therapy Is Associated with Less Post-Exercise Hyperglycemia than Multiple Daily Injections: An Observational Study of Physically Active Type 1 Diabetes Patients. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 84-88.	4.4	71
49	Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2015, 124, 119-126.	2.9	67
50	Reference values for ultrasonography of peripheral nerves. <i>Muscle and Nerve</i> , 2016, 53, 538-544.	2.2	66
51	Assessment of urinary microparticles in normotensive patients with type 1 diabetes. <i>Diabetologia</i> , 2017, 60, 581-584.	6.3	65
52	Peripheral nerve high-resolution ultrasound in diabetes. <i>Muscle and Nerve</i> , 2017, 55, 171-178.	2.2	64
53	Conduction Slowing in Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2013, 36, 3684-3690.	8.6	63
54	Identification and Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combinations of Nerve Conduction Study Parameters. <i>PLoS ONE</i> , 2013, 8, e58783.	2.5	58

#	ARTICLE	IF	CITATIONS
55	In Vivo Corneal Confocal Microscopy and Prediction of Future Incident Neuropathy in Type 1 Diabetes: A Preliminary Longitudinal Analysis. <i>Canadian Journal of Diabetes</i> , 2015, 39, 390-397.	0.8	57
56	Validation of a Novel Point-of-Care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2006, 29, 2023-2027.	8.6	53
57	Early nephropathy in type 1 diabetes: the importance of early renal function decline. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 233-240.	2.0	53
58	Early nephropathy in type 1 diabetes: A new perspective on who will and who will not progress. <i>Current Diabetes Reports</i> , 2005, 5, 455-463.	4.2	50
59	Type 1 Diabetes and Exercise: Using the Insulin Pump to Maximum Advantage. <i>Canadian Journal of Diabetes</i> , 2006, 30, 72-79.	0.8	49
60	Determinants of Progression from Microalbuminuria to Proteinuria in Patients Who Have Type 1 Diabetes and Are Treated with Angiotensin-Converting Enzyme Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 461-469.	4.5	49
61	Point Accuracy of Interstitial Continuous Glucose Monitoring During Exercise in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 46-49.	4.4	47
62	Serum Levels of Advanced Glycation Endproducts and Other Markers of Protein Damage in Early Diabetic Nephropathy in Type 1 Diabetes. <i>PLoS ONE</i> , 2012, 7, e35655.	2.5	46
63	Urinary adenosine excretion in type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F184-F191.	2.7	46
64	Prospective association of 25(OH)D with metabolic syndrome. <i>Clinical Endocrinology</i> , 2014, 80, 502-507.	2.4	44
65	Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation. <i>Science</i> , 2021, 373, 522-527.	12.6	43
66	Cooling Detection Thresholds in the Assessment of Diabetic Sensory Polyneuropathy: Comparison of CASE IV and Medoc instruments. <i>Diabetes Care</i> , 2004, 27, 1674-1679.	8.6	42
67	White blood cell subtypes, insulin resistance and β -cell dysfunction in high-risk individuals: the PROMISE cohort. <i>Clinical Endocrinology</i> , 2014, 81, 536-541.	2.4	41
68	Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in Patients with Nonmacroalbuminuric Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1136-1144.	4.5	41
69	The consequences of anxious temperament for disease detection, self-management behavior, and quality of life in Type 2 diabetes mellitus. <i>Journal of Psychosomatic Research</i> , 2009, 67, 297-305.	2.6	40
70	Rapid Corneal Nerve Fiber Loss: A Marker of Diabetic Neuropathy Onset and Progression. <i>Diabetes Care</i> , 2020, 43, 1829-1835.	8.6	40
71	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol: Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019, 42, 1454-1463.	8.6	39
72	Resistance Exercise in Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2013, 37, 420-426.	0.8	38

#	ARTICLE	IF	CITATIONS
73	Sex differences in neuropathic pain intensity in diabetes. <i>Journal of the Neurological Sciences</i> , 2018, 388, 103-106.	0.6	38
74	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. <i>JCI Insight</i> , 2018, 3, .	5.0	38
75	Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. <i>PLoS ONE</i> , 2015, 10, e0142309.	2.5	37
76	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1318-1324.	2.3	37
77	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2570-2578.	8.6	37
78	Neuropathy. <i>Canadian Journal of Diabetes</i> , 2018, 42, S217-S221.	0.8	36
79	Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?. <i>Canadian Journal of Diabetes</i> , 2014, 38, 356-363.	0.8	35
80	Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies. <i>PLoS ONE</i> , 2016, 11, e0165731.	2.5	33
81	Diagnosis and management of diabetic neuropathy. <i>Current Diabetes Reports</i> , 2002, 2, 495-500.	4.2	32
82	Heart Rate Variability and Sensorimotor Polyneuropathy in Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 809-816.	8.6	31
83	The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes – An Observational Study. <i>PLoS ONE</i> , 2014, 9, e89344.	2.5	29
84	Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. <i>Cardiovascular Diabetology</i> , 2016, 15, 14.	6.8	29
85	Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function. <i>Kidney International</i> , 2020, 97, 631-635.	5.2	29
86	Symmetry of nerve conduction studies in different stages of diabetic polyneuropathy. <i>Muscle and Nerve</i> , 2002, 25, 212-217.	2.2	28
87	Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes. <i>Diabetes</i> , 2017, 66, 1939-1949.	0.6	28
88	Corneal Confocal Microscopy Predicts the Development of Diabetic Neuropathy: A Longitudinal Diagnostic Multinational Consortium Study. <i>Diabetes Care</i> , 2021, 44, 2107-2114.	8.6	28
89	Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0141085.	2.5	28
90	Agreement between automated and manual quantification of corneal nerve fiber length: Implications for diabetic neuropathy research. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1066-1073.	2.3	26

#	ARTICLE	IF	CITATIONS
91	Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 298-307.	4.4	25
92	Diabetes Complications and the Renin-Angiotensin System. <i>New England Journal of Medicine</i> , 2009, 361, 83-85.	27.0	24
93	Multi-Site Testing With a Point-of-Care Nerve Conduction Device Can Be Used in an Algorithm to Diagnose Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2008, 31, 522-524.	8.6	23
94	The Celiac Disease and Diabetes-Dietary Intervention and Evaluation Trial (CD-DIET) protocol: a randomised controlled study to evaluate treatment of asymptomatic coeliac disease in type 1 diabetes. <i>BMJ Open</i> , 2015, 5, e008097-e008097.	1.9	23
95	Renal Hyperfiltration and Systemic Blood Pressure in Patients with Uncomplicated Type 1 Diabetes Mellitus. <i>PLoS ONE</i> , 2013, 8, e68908.	2.5	23
96	Diabetic Neuropathy and Axon Reflex-Mediated Neurogenic Vasodilatation in Type 1 Diabetes. <i>PLoS ONE</i> , 2012, 7, e34807.	2.5	22
97	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 660-664.	2.3	22
98	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. <i>Diabetes</i> , 2019, 68, 1649-1662.	0.6	22
99	Comparison of diabetes patients with demyelinating diabetic sensorimotor polyneuropathy to those diagnosed with CIDP. <i>Brain and Behavior</i> , 2013, 3, 656-663.	2.2	21
100	Diabetic Neuropathies. <i>Seminars in Neurology</i> , 2015, 35, 424-430.	1.4	21
101	A rapid decline in corneal small fibers and occurrence of foot ulceration and Charcot foot. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1437-1439.	2.3	21
102	The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. <i>PLoS ONE</i> , 2017, 12, e0186910.	2.5	21
103	Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus. <i>Diabetologia</i> , 2019, 62, 1090-1093.	6.3	21
104	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 1073-1074.	2.3	21
105	Validation of cooling detection threshold as a marker of sensorimotor polyneuropathy in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 716-722.	2.3	20
106	Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: A retrospective, population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1322-1329.	4.4	20
107	Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2x2 factorial randomized crossover trial. <i>Nature Medicine</i> , 2022, 28, 1269-1276.	30.7	20
108	Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes. <i>Diabetes Care</i> , 2016, 39, e67-e68.	8.6	19

#	ARTICLE	IF	CITATIONS
109	Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. <i>Diabetes Care</i> , 2020, 43, 1553-1556.	8.6	19
110	Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1272-1281.	4.4	19
111	No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?. <i>American Journal of Kidney Diseases</i> , 2016, 68, 349-352.	1.9	18
112	Frequent laboratory abnormalities in CIDP patients. <i>Muscle and Nerve</i> , 2016, 53, 862-865.	2.2	18
113	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. <i>Diabetes Care</i> , 2018, 41, 88-95.	8.6	17
114	Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2466-2475.	4.4	17
115	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 273-280.	8.6	16
116	Sural-to-radial amplitude ratio in the diagnosis of diabetic sensorimotor polyneuropathy. <i>Muscle and Nerve</i> , 2012, 45, 126-127.	2.2	15
117	The impact of common variation in the definition of diabetic sensorimotor polyneuropathy on the validity of corneal in vivo confocal microscopy in patients with type 1 diabetes: a brief report. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 240-242.	2.3	15
118	Using in vivo corneal confocal microscopy to identify diabetic sensorimotor polyneuropathy risk profiles in patients with type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000251.	2.8	15
119	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. <i>American Journal of Kidney Diseases</i> , 2019, 73, 786-796.	1.9	15
120	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 575-583.	4.4	15
121	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetologia</i> , 2017, 60, 2529-2531.	6.3	14
122	Measurement of Cooling Detection Thresholds for Identification of Diabetic Sensorimotor Polyneuropathy in Type 1 Diabetes. <i>PLoS ONE</i> , 2014, 9, e106995.	2.5	14
123	Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 537-546.	3.0	13
124	Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. <i>Journal of the Neurological Sciences</i> , 2017, 372, 223-227.	0.6	13
125	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 831-839.	8.6	13
126	Kidney Effects of Empagliflozin in People with Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1715-1719.	4.5	13

#	ARTICLE	IF	CITATIONS
127	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. PLoS ONE, 2018, 13, e0196647.	2.5	13
128	Higher magnification lenses versus conventional lenses for evaluation of diabetic neuropathy by corneal in vivo confocal microscopy. Diabetes Research and Clinical Practice, 2012, 97, e37-e40.	2.8	12
129	Uric acid levels correlate with the severity of diabetic sensorimotor polyneuropathy. Journal of the Neurological Sciences, 2017, 379, 94-98.	0.6	12
130	Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?. Canadian Journal of Diabetes, 2017, 41, 6-9.	0.8	12
131	Estimating GFR by Serum Creatinine, Cystatin C, and \hat{I}^2 -Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. Kidney International Reports, 2019, 4, 786-796.	0.8	12
132	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1388-1398.	4.4	12
133	Discoveries from the study of longstanding type 1 diabetes. Diabetologia, 2021, 64, 1189-1200.	6.3	12
134	Emerging Therapies for Diabetic Neuropathy: A Clinical Overview. Current Diabetes Reviews, 2005, 1, 271-280.	1.3	11
135	Disease activity in chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences, 2016, 369, 204-209.	0.6	11
136	Analysis of Prevalence, Magnitude and Timing of the Dawn Phenomenon in Adults and Adolescents With Type 1 Diabetes: Descriptive Analysis of 2 Insulin Pump Trials. Canadian Journal of Diabetes, 2020, 44, 229-235.	0.8	11
137	Resistance Exercise in Already-Active Diabetic Individuals (READI): Study rationale, design and methods for a randomized controlled trial of resistance and aerobic exercise in type 1 diabetes. Contemporary Clinical Trials, 2015, 41, 129-138.	1.8	10
138	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. Diabetes Care, 2019, 42, 1716-1723.	8.6	10
139	High fractional excretion of glycation adducts is associated with subsequent early decline in renal function in type 1 diabetes. Scientific Reports, 2020, 10, 12709.	3.3	10
140	Baseline omega-3 level is associated with nerve regeneration following 12-months of omega-3 nutrition therapy in patients with type 1 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107798.	2.3	10
141	Objective Evidence for the Reversibility of Nerve Injury in Diabetic Neuropathic Cachexia. Diabetes Care, 2006, 29, 473-474.	8.6	9
142	Can Improved Glycemic Control Slow Renal Function Decline at All Stages of Diabetic Nephropathy?. Seminars in Nephrology, 2012, 32, 423-431.	1.6	9
143	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. BMJ Open Diabetes Research and Care, 2017, 5, e000461.	2.8	9
144	Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination. PLoS ONE, 2015, 10, e0139674.	2.5	9

#	ARTICLE	IF	CITATIONS
145	Early Vascular Risk Factor Modification in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2005, 352, 408-409.	27.0	8
146	Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates. <i>PLoS ONE</i> , 2015, 10, e0139689.	2.5	8
147	Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes. <i>Clinical Neurophysiology</i> , 2018, 129, 122-126.	1.5	8
148	Sex differences in neuropathy & neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107397.	2.3	8
149	Low-dose empagliflozin as adjunct-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 427-433.	4.4	8
150	Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107807.	2.3	8
151	Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107880.	2.3	8
152	Impact of a Gluten-Free Diet on Quality of Life and Health Perception in Patients With Type 1 Diabetes and Asymptomatic Celiac Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1984-e1992.	3.6	7
153	Impact of government-funded insulin pump programs on insulin pump use in Canada: a cross-sectional study using the National Diabetes Repository. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002371.	2.8	7
154	How sensitive is the case definition for diabetic sensorimotor polyneuropathy to the use of different symptoms, signs, and nerve conduction parameters in Type 1 diabetes?. <i>Diabetes Research and Clinical Practice</i> , 2011, 92, e16-e19.	2.8	6
155	Ability of Cystatin C to Detect Changes in Glomerular Filtration Rate After ACE Inhibition in Patients with Uncomplicated Type 1 Diabetes. <i>Clinical and Experimental Hypertension</i> , 2012, 34, 606-611.	1.3	6
156	Choosing drugs for the treatment of diabetic neuropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1805-1814.	1.8	6
157	Sensor-Augmented Pump and Multiple Daily Injection Therapy in the United States and Canada: Post-Hoc Analysis of a Randomized Controlled Trial. <i>Canadian Journal of Diabetes</i> , 2015, 39, 50-54.	0.8	5
158	Nerve function varies with hemoglobin A1c in controls and type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 424-428.	2.3	5
159	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108134.	2.3	5
160	Evaluation of a Clinical Tool to Test and Adjust the Programmed Overnight Basal Profiles for Insulin Pump Therapy: A Pilot Study. <i>Canadian Journal of Diabetes</i> , 2015, 39, 364-372.	0.8	4
161	Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	4
162	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. <i>Renal Failure</i> , 2019, 41, 427-433.	2.1	4

#	ARTICLE	IF	CITATIONS
163	Uric Acid Levels Correlate with Sensory Nerve Function in Healthy Subjects. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 337-341.	0.5	4
164	Talking Points for Helping Your Type 1 Diabetes Patient Decide About Hybrid Closed Loop. <i>Canadian Journal of Diabetes</i> , 2020, 44, 356-358.	0.8	4
165	Rethinking Neuropathy in Type 1 Diabetes: Had We Lost Sight of What Matters Most?. <i>Diabetes Care</i> , 2020, 43, 695-697.	8.6	4
166	Afternoon aerobic and resistance exercise have limited impact on 24-h CGM outcomes in adults with type 1 diabetes: A secondary analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108874.	2.8	4
167	The Prevalence of Autoimmune Diseases in Longstanding Diabetes: Results from the Canadian Study of Longevity in Adults with Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2021, 45, 512-518.e1.	0.8	4
168	Allopurinol adherence, persistence and patterns of use in individuals with diabetes and gout: A retrospective, population-based cohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1162-1169.	3.4	4
169	SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. <i>Current Diabetes Reports</i> , 2022, 22, 317-332.	4.2	4
170	Dorsal versus ventral monofilament testing of the great toe for the identification of diabetic sensorimotor polyneuropathy. <i>Diabetes Research and Clinical Practice</i> , 2011, 93, e71-e73.	2.8	3
171	Point Accuracy of Interstitial Continuous Glucose Monitoring During Resistance and Aerobic Exercise in Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2012, 36, S14-S15.	0.8	3
172	Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 346-349.	0.5	3
173	Sounding the alarm on rising diabetes-related amputations. <i>Cmaj</i> , 2019, 191, E953-E954.	2.0	3
174	SGLT2a inhibition reverts urinary peptide changes associated with severe COVIDa19: An in silico proof of principle of proteomicsa based drug repurposing. <i>Proteomics</i> , 2021, 21, e2100160.	2.2	3
175	Allopurinol and Renal Outcomes in Adults With and Without Type 2 Diabetes: A Retrospective, Population-Based Cohort Study and Propensity Score Analysis. <i>Canadian Journal of Diabetes</i> , 2021, 45, 641-649.e4.	0.8	3
176	The uncomfortable truth about kidney disease in type 1 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 472-473.	11.4	3
177	Meta-analysis of artificial pancreas trials: methodological considerations a€“ Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 685-686.	11.4	2
178	Vitamin D Levels and the Risk of Posttransplant Diabetes Mellitus After Kidney Transplantation. <i>Progress in Transplantation</i> , 2021, 31, 133-141.	0.7	2
179	Orthostatic blood pressure changes and diabetes duration. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108169.	2.3	2
180	The clinical landscape of painful diabetic neuropathy therapy: perspectives for clinicians from clinical practice guidelines. <i>Clinical Investigation</i> , 2012, 2, 483-489.	0.0	1

#	ARTICLE	IF	CITATIONS
181	Response to Comment on Breiner et al. Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients? <i>Diabetes Care</i> 2014;37:1418-1424. <i>Diabetes Care</i> , 2014, 37, e242-e242.	8.6	1
182	126 - Prevalence of Detectable C-peptide in Longstanding Type 1 Diabetes (T1D). <i>Canadian Journal of Diabetes</i> , 2019, 43, S43.	0.8	1
183	Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 547-549.	2.3	1
184	Graves' Disease After Chronic Hypothyroidism in Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2020, 44, 131-132.	0.8	1
185	Glycaemic control in transition-aged versus early adults with type 1 diabetes and the effect of a government-funded insulin pump programme. <i>Diabetic Medicine</i> , 2021, 38, e14618.	2.3	1
186	Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy. <i>Current Diabetes Reviews</i> , 2021, 17, .	1.3	1
187	Impact of government-funded insulin pump programs on insulin pump use in Canada: a cross-sectional study using the National Diabetes Repository. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, .	2.8	1
188	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 585-593.	8.6	1
189	Identification and 4-year Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combinations of Nerve Conduction Study Parameters. <i>Canadian Journal of Diabetes</i> , 2012, 36, S51-S52.	0.8	0
190	Validation of Cooling Detection Threshold as a Marker of Sensorimotor Polyneuropathy in Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2015, 39, 542.	0.8	0
191	Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. <i>Canadian Journal of Diabetes</i> , 2015, 39, 543.	0.8	0
192	High frequency of MGUS in DSP. <i>Muscle and Nerve</i> , 2018, 57, 1018-1021.	2.2	0
193	Authors' reply to: "The role of long-term effects of allopurinol on cardiovascular outcomes and all-cause mortality in diabetes". <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2181-2182.	4.4	0
194	18 - Empagliflozin Is Associated With Increased Plasma Lipid Metabolites in Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2020, 44, S7-S8.	0.8	0
195	Performing Resistance Exercise Prior to Aerobic Exercise Results in Higher Growth Hormone Levels during Exercise in Physically Active Individuals with Well-Controlled Type 1 Diabetes. <i>FASEB Journal</i> , 2013, 27, 712.29.	0.5	0